Product Description
Molecular Diagnostics at the Point of Care by Application, Technology, Place, Product and Country with Executive Guides and Customization 2023 to 2027
Publication date: November 7, 2022
Page count: 435
Infectious disease diagnostics are changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.
- Are targeted tests for specific pathogens going to be obsolete?
- Will diagnostics replace physicians?
Point of Care testing is proving itself in the market. Players are reporting double digit growth. Lowering costs, improving outcomes and even helping in the battle against Antimicrobial Resistance (AMR). Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time.
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it.
Make projections with confidence using the latest data.
If a country forecast is not already listed, purchasers can request individual country market size information, or other customization, without additional charge with the corporate license.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School
